COVID-19: Indian Drug Regulator gives approval to Glenmark drug Favipiravir as Coronavirus treatment for mild to moderate patients

Drug firm Glenmark Pharmaceuticals on Friday said it has received approval from the Indian drug regulator to launch oral antiviral drug Favipiravir for treatment of mild to moderate COVID-19 patients in the country.

Glenmark Pharmaceuticals said in a statement, “It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.”

The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.

Glenmark said, “This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the Covid-19 outbreak.”

Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time